Back to top
more

ABCELLERA BIOLG (ABCL)

(Delayed Data from NSDQ)

$11.32 USD

11.32
4,543,127

-0.25 (-2.16%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $11.26 -0.06 (-0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +29.41% and +146.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 11.76% and 49.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 26.67% and 40.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?